Gujarat Inject Kerala Ltd Stock Price Today (NSE: GUJINJEC)

Gujarat Inject Kerala Ltd

109.100.90 (0.82%)
Market Closed

Fundamental Score

...

Gujarat Inject Kerala Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Gujarat Inject Kerala Ltd share price today is 109.10, down 0.82% on NSE/BSE as of 22 June 2026. Gujarat Inject Kerala Ltd (GUJINJEC) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 41.42 (Cr). The 52-week high for GUJINJEC share price is 116.25 and the 52-week low is 19.01. At a P/E ratio of 98.61x, GUJINJEC is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 11.00% and a debt-to-equity ratio of 0.00.

Gujarat Inject Kerala Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
116.25
Low
101.05
Volume
41.9K
Change
+3.66%

Gujarat Inject Kerala Ltd share price chart: 3.66% return over the past month. 52-week high ₹116.25, 52-week low ₹19.01.

Gujarat Inject Kerala Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
110.00111.95109.00109.1033.22K (Cr)
110.00115.30108.00110.0036.35K (Cr)
110.10116.25110.10112.2551.73K (Cr)
112.25113.00109.00113.0066.21K (Cr)
112.55112.55112.55112.5594.78K (Cr)
107.20107.20105.80107.2019.90K (Cr)
102.10103.50102.10102.1070.84K (Cr)
101.05105.15101.05103.502.49L (Cr)
103.10103.10103.00103.1017.18K (Cr)
107.00107.10102.90102.9032.40K (Cr)

Gujarat Inject Kerala Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
110.00115.30108.00109.10-0.82%
105.25116.25101.05112.25+6.65%
82.12103.2078.00103.20+25.67%
64.2078.2263.4078.21+21.82%
49.9864.7049.9864.20+28.45%
35.7549.2835.7548.69+36.20%
28.4036.4027.9835.75+25.88%
23.9929.3023.2328.28+17.88%
20.0124.0019.5123.47+17.29%
21.5021.5019.0120.02-6.88%
22.6022.9820.3021.74-3.81%
23.9125.2821.9022.49-5.94%

AI Research Briefing

Powered by Gemini · 2026-04-04

Overvalued micro-cap with deteriorating financials and no clear growth drivers.

Research Confidence
4.0/10Low
SME DARK HORSEConsolidation based on 1M/3M/6M returns, but near 52 week high.Expensive vs industry P/E due to high stock price and low earnings.

Macro backdrop

Why Now
  • High valuation relative to industry
  • Recent negative quarterly results
  • Negative free cash flow
Potential Catalysts
  • Significant improvement in quarterly sales and profit
  • New order wins or expansion announcements
  • Positive change in promoter holding
Key Risks
  • High P/E ratio
  • Negative free cash flow
  • Declining quarterly performance
Institutional Activity

No institutional interest; zero promoter holding.

Macro Context

Pharmaceutical sector facing mixed signals and regulatory scrutiny.

Order Book / Expansion

No major company-specific news in the last 3 weeks

Cash Flow Quality

Poor - negative free cash flow over the past 5 years.

3–6 Month Outlook

Uncertain due to inconsistent performance and lack of growth drivers.

Primary Thesis Risk

Liquidity risk and high valuation make this a risky investment.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Poor

Return on Equity (ROE)

11.00%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

13.48%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

2.32%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Gujarat Inject Kerala Ltd Valuation Check

Poor

Price to Earnings (P/E)

98.61x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Poor

Promoter Holding

0.00%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-88.52%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

-81.65%

Revenue growth vs same quarter last year

Revenue Growth (5-Year CAGR)

N/A

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

104.89%

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.00x

Total debt ÷ equity. Below 0.5 = financially healthy

Interest Coverage Ratio

N/A

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-9.61 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Gujarat Inject Kerala Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of GUJINJEC across key market metrics for learning purposes.

Positive Indicators

3 factors identified

Excellent EPS Growth (104.89% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Debt-Free Balance Sheet (D/E: 0.00)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

7 factors identified

Margin Pressure Concerns (2.32%)

Observation: Operating margins are below industry standards.

Analysis: OPM <5% may indicate pricing pressures or cost management challenges.

Premium Valuation Risk (P/E: 98.61x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

Profit Decline Concern (-88.52%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Revenue Contraction (-81.65%)

Observation: Sales decline may indicate market challenges or competitive pressures.

Analysis: Negative revenue growth requires analysis of market conditions.

Negative Free Cash Flow (₹-9.61 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Low Promoter Commitment (0.00%)

Observation: Reduced promoter stake may indicate limited confidence.

Analysis: Low promoter holding may raise questions about management commitment.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Gujarat Inject Kerala Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Gujarat Inject Kerala Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
12.1/100
109
₹41.42
98.6
Average
11.00%
Average
13.48%
Average
0.0
Excellent
0.00%
65.2/100
1782
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6623
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4421
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1401
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1278
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2268
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
1089
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2336
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1462
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5252
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

Gujarat Inject Kerala Ltd PE Ratio History

Historical price-to-earnings ratio for GUJINJEC — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20240.07₹25.39362.7x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Gujarat Inject Kerala Ltd Dividend History

Annual cash dividends paid by GUJINJEC — dividend yield N/A

Financial YearDividends Paid (₹ Cr)
FY 20220.00 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Gujarat Inject Kerala Ltd Quarterly Performance

Latest quarterly metrics for GUJINJEC — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

-81.65%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-88.52%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

N/A

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Gujarat Inject Kerala Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for GUJINJEC — calculated from daily price history

50RSI 14
Neutral — RSI 50

Momentum is balanced — neither overbought nor oversold.

SMA 50
95
▲ Price above SMA 50 — Short-term bullish
SMA 200
49
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
38K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Gujarat Inject Kerala Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Gujarat Inject Kerala Ltd (GUJINJEC) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Gujarat Inject Kerala Ltd

About GUJINJEC (Gujarat Inject Kerala Ltd)

Gujarat Inject Kerala Ltd is a dynamic pharmaceutical entity making significant strides in the Indian healthcare landscape. Rooted in a commitment to quality and innovation, the co...mpany diligently sources and distributes a wide array of pharmaceutical products, catering to diverse therapeutic needs. With a strong emphasis on ethical practices and regulatory compliance, GUJINJEC strives to ensure that patients and healthcare professionals have access to reliable and effective medications. Their extensive network and strategic partnerships enable them to efficiently navigate the complexities of the pharmaceutical supply chain, ensuring timely delivery and consistent availability of vital medicines. The company's operations are characterized by a customer-centric approach, focusing on building strong relationships with pharmacies, hospitals, and medical practitioners. GUJINJEC's dedicated team works tirelessly to understand the evolving needs of the market and respond proactively with tailored solutions. This dedication extends beyond mere product distribution; they aim to provide comprehensive support to their partners, fostering a collaborative environment that promotes better patient outcomes. By staying abreast of the latest advancements in pharmaceutical research and technology, GUJINJEC endeavors to contribute to the overall improvement of healthcare standards in India. Operating from its base in Vadodara, India, GUJINJEC leverages its strategic location to efficiently manage its nationwide distribution network. The company maintains a robust infrastructure and adheres to stringent quality control measures throughout its operations. Furthermore, GUJINJEC is committed to sustainable business practices, actively seeking opportunities to minimize its environmental impact and contribute to the well-being of the communities it serves. The company’s unwavering focus on integrity, quality, and customer satisfaction positions it as a trusted and reliable partner in the Indian pharmaceutical industry.

Company Details

Symbol:GUJINJEC
Industry:Pharmaceuticals
Sector:Pharmaceuticals
Website:N/A

Key Leadership

Mr. Murli Shivshankaran Nair
MD, Chairman & Whole-Time Director
Mr. Deepak Diwan Bachwani
CFO & Executive Director
Ms. Manmeetkaur Harshdeepsingh Bhatia
Company Secretary & Compliance Officer

GUJINJEC Share Price: Frequently Asked Questions

What is the current share price of Gujarat Inject Kerala Ltd?

Gujarat Inject Kerala Ltd (GUJINJEC) trades at ₹109.10 on NSE and BSE. Market cap ₹41.42 (Cr). Educational data only.

What is the P/E ratio of Gujarat Inject Kerala Ltd?

Gujarat Inject Kerala Ltd has a P/E of 98.61x vs industry average 31.77x.

What is the Bull Run score for Gujarat Inject Kerala Ltd?

Gujarat Inject Kerala Ltd has a Bull Run score of 12.1/100 based on 25+ financial parameters.

Does Gujarat Inject Kerala Ltd pay dividends?

Gujarat Inject Kerala Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Gujarat Inject Kerala Ltd?

Gujarat Inject Kerala Ltd has ROE of 11.00%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Gujarat Inject Kerala Ltd?

Gujarat Inject Kerala Ltd has debt-to-equity of 0.00.

Is Gujarat Inject Kerala Ltd a good investment?

Bull Run gives Gujarat Inject Kerala Ltd a score of 12.1/100. This is not investment advice — consult a SEBI-registered advisor.